Physician profile
Tal Buntinx
NPI 1013446590
$3,265.98
in general payments reported to CMS, 2019-2025
15 companies · $830 in 2025
The $830 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $367 · 2020: $103 · 2021: $374 · 2022: $271 · 2023: $659 · 2024: $661 · 2025: $830.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,951 · Education: $199.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,950.61 |
| Education | $198.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $634.67 | 2020-2025 | Otezla, Otezla |
| Pfizer INC. | $518.66 | 2022-2025 | |
| Janssen Biotech, INC. | $442.18 | 2019-2025 | Tremfya, Simponi, Stelara |
| Novartis Pharmaceuticals Corporation | $311.19 | 2025 | |
| Genzyme Corporation | $243.37 | 2022-2024 | |
| Abbvie INC. | $228.32 | 2019-2024 | |
| Leo Pharma INC. | $220.80 | 2023-2025 | Adbry |
| Regeneron Healthcare Solutions, INC. | $213.41 | 2019-2022 | |
| Vyne Pharmaceuticals INC. | $119.64 | 2021 | |
| Allergan, INC. | $80.46 | 2019 | |
| Organon LLC | $74.74 | 2025 | Vtama |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $73.09 | 2025 | Cabtreo |
| Lilly USA, LLC | $53.88 | 2023-2025 | Taltz, Ebglyss, Olumiant |
| Galderma Laboratories, L.P. | $34.40 | 2025 | Nemluvio |
| Dermavant Sciences, INC. | $17.17 | 2024 | Vtama |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tal Buntinx listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.